Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
NEVRO CORP (NVRO) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/01/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/01/2023 8-K Quarterly results
07/07/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
06/12/2023 SC 13G/A FMR LLC reports a 9.1% stake in NEVRO CORP
05/30/2023 8-K Appointed a new director
05/23/2023 SD Form SD - Specialized disclosure report:
04/26/2023 10-Q Quarterly Report for the period ended March 31, 2023
04/26/2023 8-K Quarterly results
04/21/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
04/19/2023 8-K Quarterly results
02/14/2023 SC 13G/A PRICE T ROWE ASSOCIATES INC reports a 0.7% stake in NEVRO CORP
02/09/2023 SC 13G/A FMR LLC reports a 14.7% stake in NEVRO CORP
01/23/2023 SC 13G/A BlackRock Inc. reports a 13% stake in NEVRO CORP
01/20/2023 SC 13G NORGES BANK reports a 5.1% stake in Nevro Corp
01/09/2023 8-K Results of Operations and Financial Condition, Departure of Directors or Certain Officers; Election of Directors; Appointment...
Docs: "Nevro Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2022 Revenue and Provides Full-Year 2023 Revenue Guidance Company Announces 2023 Retirement Plans of D. Keith Grossman from Positions of CEO and President; Will Remain as Chairman of the Board Company to Present Today at J.P. Morgan Healthcare Conference at 3:45 pm Pacific Time REDWOOD CITY, California – January 9, 2023 – Nevro Corp. , a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced its preliminary, unaudited fourth quarter and full-year 2022 revenue results. The company also provided full-year 2023 revenue guidance and announced its Chief Executive Officer and President, D. Keith Grossman, has informed the Board of his intention t..."
11/07/2022 SC 13G/A Jackson Square Partners, LLC reports a 0% stake in Nevro Corp.
11/02/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/02/2022 8-K Quarterly results
09/12/2022 SC 13G FMR LLC reports a 10.6% stake in NEVRO CORP
09/09/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/03/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/03/2022 8-K Quarterly results
Docs: "Nevro Reports Second Quarter 2022 Financial Results, Provides Third Quarter 2022 Guidance and Updates Full-Year 2022 Guidance"
08/01/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Nevro and Boston Scientific Announce the Settlement of Their Ongoing Intellectual Property Litigations Parties Reach an Agreement that Concludes Outstanding Intellectual Property Disputes"
07/11/2022 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
05/31/2022 8-K Quarterly results
05/23/2022 SD Form SD - Specialized disclosure report:
05/04/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/04/2022 8-K Quarterly results
04/11/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/11/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
02/23/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
02/23/2022 10-K Annual Report for the period ended December 31, 2021
02/23/2022 8-K Quarterly results
Docs: "Nevro Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides First Quarter and Full-Year 2022 Guidance"
02/11/2022 SC 13G Jackson Square Partners, LLC reports a 7% stake in Nevro Corp.
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy